This inventor holds 3 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignees: Shanghai Cell Therapy Group Co., Ltd., China Unionpay Co., Ltd., Shanghai Cell Therapy Research Institute. Active years: 2022-2025.
Company Filing History:
2 out of 2 
1 out of 118 
1 out of 1 Years Active: 2022-2025
Title: Zhou He: Innovator in Antibody-Modified T Cell Technology
Introduction
Zhou He is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapies for malignant tumors. With a total of 3 patents to his name, Zhou He is recognized for his groundbreaking work in the area of chimeric antigen receptor (CAR) modified T cells.
Latest Patents
Zhou He's latest patents include two notable inventions. The first patent, titled "Antibody-modified chimeric antigen receptor modified T cell and uses thereof," describes a T cell that expresses an antibody or contains the coding sequence of the antibody. This invention focuses on a T cell that is a CAR-T cell, which is designed for treatment applications in malignant tumors. The second patent, "Killer cell capable of efficiently and stably expressing antibody, and uses thereof," involves a transgenic killer cell with a genome that integrates a coding sequence comprising an antibody of a human Fc section. This invention also includes a pharmaceutical composition that utilizes the transgenic killer cell.
Career Highlights
Throughout his career, Zhou He has worked with several notable companies, including Shanghai Cell Therapy Group Co., Ltd. and China UnionPay Co., Ltd. His experience in these organizations has contributed to his expertise in the field of cell therapy and biotechnology.
Collaborations
Zhou He has collaborated with esteemed colleagues such as Qijun Qian and Huajun Jin. These partnerships have further enhanced his research and development efforts in innovative therapies.
Conclusion
Zhou He is a distinguished inventor whose work in antibody-modified T cell technology has the potential to revolutionize cancer treatment. His contributions to the field are marked by his innovative patents and collaborations with other experts.